We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Genaissance Enters Pharmacogenomic Collaboration with Otsuka
News

Genaissance Enters Pharmacogenomic Collaboration with Otsuka

Genaissance Enters Pharmacogenomic Collaboration with Otsuka
News

Genaissance Enters Pharmacogenomic Collaboration with Otsuka

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Genaissance Enters Pharmacogenomic Collaboration with Otsuka "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Genaissance Pharmaceuticals, Inc. has announced that it has entered into a pharmacogenomic research collaboration with Otsuka Pharmaceutical Co., Ltd.

Under the terms of the agreement, Genaissance will apply its HAP™ Technology with the goal of identifying genetic markers related to drug response.

Genaissance and Otsuka will be co-owners of the intellectual property that results from the collaboration and both companies will be eligible to receive royalties on revenues generated from diagnostic products resulting from the collaboration.

"We are very pleased that we will be collaborating with Otsuka," said Kevin Rakin, President and Chief Executive Officer of Genaissance Pharmaceuticals.

"We believe this agreement is another indication that pharmacogenomics is becoming an important tool for drug development."

Advertisement